title: Frequency and phenotyping of human immunodeficiency virus (HIV)-specific CD8+ T cells in HIV-infected children, using major histocompatibility complex class I peptide tetramers.
abstract: HLA-A*02 tetramers complexed to human immunodeficiency virus (HIV) Gag SLYNTVATL and HIV Pol ILKEPVHGV peptides were used to characterize HLA class I-restricted CD8(+) T cells in 41 HIV-infected children. The frequencies and the phenotype of specific circulating CD8(+) T cells were determined in whole-blood samples by means of cytometric analysis. Background staining of 13 HLA-A*02-negative patients showed that the frequency of CD8(+) T cells was <0.01%. Of the 28 HLA-A*02-positive patients, blood samples from 26 stained positive at least once the Gag tetramer (mean CD8(+) T cells, 0.87%; range, 0.1%-3.9%), and blood samples from 21 stained positive for the Pol tetramer (mean CD8(+) T cells, 0.59%; range, 0.1%-5.5%). The tetramer-binding cells were CD28(-), CD45RA(-), CD45RO(+), HLA-DR(+), and CD69(-) T lymphocytes. HIV-specific CD8(+) T cells can be detected easily in peripheral blood of HIV-infected children, using HLA tetramers combined with HIV peptides. These cells are memory activated CD28(-)CD8(+) T lymphocytes.
authors.affiliation: Unité d'Immunohématologie-Immunopathologie, Centre National de la Recherche Scientifique Unité de Recherche Associée 1930, Institut Pasteur, Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Scott-Algara
authors.forename: F
authors.initials: F
authors.lastname: Buseyne
authors.forename: S
authors.initials: S
authors.lastname: Blanche
authors.forename: C
authors.initials: C
authors.lastname: Rouzioux
authors.forename: C
authors.initials: C
authors.lastname: Jouanne
authors.forename: F
authors.initials: F
authors.lastname: Romagné
authors.forename: Y
authors.initials: Y
authors.lastname: Rivière
mesh_terms: D000293:Adolescent; D019380:Anti-HIV Agents / Q000627:therapeutic use; D015703:Antigens, CD / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D018106:CD28 Antigens / Q000032:analysis; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005434:Flow Cytometry; D005500:Follow-Up Studies; D015683:Gene Products, gag / Q000032:analysis; D015684:Gene Products, pol / Q000032:analysis; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000276:immunology* / Q000302:isolation & purification; D015234:HLA-A Antigens / Q000032:analysis; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D016130:Immunophenotyping; D037181:Lectins, C-Type; D017493:Leukocyte Common Antigens / Q000032:analysis; D018655:Lymphocyte Count; D019562:Viral Load; D000099192:CD69 Antigens
chemical_list: D019380:Anti-HIV Agents; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D018106:CD28 Antigens; D015683:Gene Products, gag; D015684:Gene Products, pol; D015234:HLA-A Antigens; D006684:HLA-DR Antigens; D037181:Lectins, C-Type; D017493:Leukocyte Common Antigens; D000099192:CD69 Antigens